LM-103 is under clinical development by Suzhou BlueHorse Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LM-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LM-103 overview

LM-103 is under development for the treatment of melanoma, non-small cell lung cancer, cervical cancer and other solid tumors. The therapeutic candidate comprises of autologous tumor infiltrating lymphocytes (TILs) and is administered through intravenous route.

Suzhou BlueHorse Therapeutics overview

Suzhou BlueHorse Therapeutics (BlueHorse Therapeutics) operate in healthcare sector. BlueHorse Therapeutics is headquartered in Suzhou, Jiangsu, China.

For a complete picture of LM-103’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.